Event context and recent trading performance

Surgery Partners (SGRY) has been drawing investor attention after a stretch of mixed trading, with the stock up about 1% over the past day but showing weaker performance over the past week and month.

Over the past 3 months and past year, returns have been negative, and the stock now trades near US$14.08. That backdrop is prompting closer scrutiny of the company’s fundamentals and current valuation signals.

That 1 day share price return of 1.15% sits against weaker recent momentum, with a 90 day share price return of an 18.99% decline and a 1 year total shareholder return of a 41.26% decline, suggesting sentiment has been fading despite the latest uptick around US$14.08.

If this kind of pullback has you considering fresh ideas in healthcare, it could be a good moment to scan a focused list of 31 healthcare AI stocks for potential alternatives.

With Surgery Partners posting mixed share returns, ongoing revenue growth of 6.24% and a recent net income loss of US$77.9m, is the current US$14.08 price a reset that offers upside or is the market already pricing in future growth?

Most Popular Narrative: 44.7% Undervalued

At a last close of $14.08 against a narrative fair value estimate of about $25.45, Surgery Partners is framed as materially discounted, and that view leans heavily on how its facilities are expected to capture more complex surgical volumes over time.

Disciplined execution on M&A and portfolio optimization, including accretive acquisitions and potential asset sales or health system partnerships, should enhance margin expansion, accelerate deleveraging, and improve free cash flow conversion, supporting improvements in net margins and long-term earnings power.

Curious what kind of revenue growth, margin lift, and valuation multiple are baked into that fair value? The underlying narrative leans on ambitious profitability and a richer future earnings profile.

Result: Fair Value of $25.45 (UNDERVALUED)

However, that upside story can crack if rising interest costs squeeze cash flows, or if slower acquisitions and divestitures disrupt revenue and pressure margins.

Next Steps

If this mix of pressure and potential has you on the fence, it is worth taking a closer look now and weighing the positive signals yourself. You can quickly cross check what the market might be optimistic about through our breakdown of 3 key rewards.

Looking for more investment ideas?

If you stop with just one stock, you risk missing out on other setups that could fit your goals, so broaden your watchlist with a few targeted screens.

• Spot potential value opportunities by checking companies our screener flags as 47 high quality undervalued stocks based on their fundamentals and pricing signals.
• Prioritize peace of mind by scanning 77 resilient stocks with low risk scores that score well on stability and lower overall risk profiles.
• Hunt for earlier stage opportunities with 30 elite penny stocks with strong financials that still show signs of financial strength rather than just speculative hype.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.